Nautilus Biotechnology, Inc. (NAUT)

Market Cap	210.95M
Revenue (ttm)	n/a
Net Income (ttm)	-70.21M
Shares Out	125.56M
EPS (ttm)	-0.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,585
Open	1.780
Previous Close	1.760
Day's Range	1.650 - 1.780
52-Week Range	1.650 - 3.455
Beta	0.97
Analysts	Hold
Price Target	3.58 (+113.1%)
Earnings Date	Oct 29, 2024

About NAUT

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 167
• Stock Exchange: NASDAQ
• Ticker Symbol: NAUT
• Website: https://www.nautilus.bio

Analyst Forecast

According to 3 analysts, the average rating for NAUT stock is "Hold." The 12-month stock price forecast is $3.58, which is an increase of 113.10% from the latest price.

Price Target

$3.58

(113.10% upside)

Analyst Consensus: Hold